Neželjeni događaji povezani sa trombocitaferezom kod davaoca: 10-godišnje iskustvo iz Vojvodine, Srbija
Sažetak
Uvod/Cilj. Trombocitafereza je medicinski postupak prikupljanja trombocita davaoca od koje pacijenti primaoci imaju mnogo prednosti. Postupak traje oko jedan sat i davaoci ga dobro podnose. Ipak, neželjeni događaji (ND) se mogu javiti, kako tokom, tako i nakon postupka trombocitafereze. Cilj rada bio je da se utvrdi učestalost i vrsta ND povezanih sa trombocitaferezom kod davaoca. Metode. Retrospektivna analiza ND povezanih sa trombocitaferezom sprovedena je u Zavodu za transfuziju krvi Vojvodine u periodu od 1. januara 2010. do 31. decembra 2019. godine. Rezultati. Od 2 073 davaoca trombocita, 94,84% su bili višestruki davaoci krvi, uglavnom muškarci (98,55%). ND identifikovani su tokom 180 (8,68%) trombocitafereza, bez statistički značajne razlike u pojavi između novih davalaca (10,28%) i višestrukih davalaca (8,59%). Blage lokalne reakcije povezane sa venskim pristupom (42,22%) bile su najčešći ND. Generalizovane simptome pokazalo je 16,67% davalaca, simptome koji se odnose na aferezu (citratne reakcije) 26,11% davalaca, dok je 15% davalaca imalo druge komplikacije. ND su se desili uglavnom tokom izvođenja trombocitafereze (95,55%), a svega 4,45% nakon nje. Zaključak. Trombocitafereza je, generalno, siguran postupak koji davaoci dobro podnose. Razumevanje faktora rizika od moguće pojave ND omogućava donošenje mera za njihovo sprečavanje.
Reference
Dogu MH, Hacioglu S. Analysis of plateletpheresis donor defer-ral rate, characteristics, and its preventability. J Appl Hematol 2017; 8: 12‒5.
Kaufman RM, Đulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015; 162(3): 205‒13.
Estcourt LJ, Malouf R, Hopewell S, Doree C, Van Veen J. Use of platelet transfusions prior to lumbar punctures or epidural an-aesthesia for the prevention of complications in people with thrombocytopenia. Cochrane Database Syst Rev 2018; 4: CD011980.
Squires JE. Indications for platelet transfusion in patients with thrombocytopenia. Blood Transfus 2015; 13(2): 221–6.
Ferber T, Hannan M. Donor Apheresis. In: Linz W, Chhibber V, Hoffman J, Torloni A, Vrielink H, Mason H, et al, editors. Principles of Apheresis Technology: Technical Principles of Apheresis Medicine. 6th ed. BC. Vancouver, BC: ASFA; 2017. p. 143‒62.
Grujic J, Gulan Z, Budakov Z. Importance of hemovigilance and reports on transfusion reaction in blood component therapy. Med Pregl 2012; 65(1‒2): 50‒3. (Serbian)
Heuft HG, Fischer E, Weingand T, Burkhardt T, Leitner G, Baume H, et al. Donor Safety in Haemapheresis: Development of an Internet-Based Registry for Comprehensive Assessment of Adverse Events from Healthy Donors. Transfus Med Hemother 2017; 44(3): 188‒200.
Standard for Surveillance of Complications Related to Blood Donation. Working Group on Donor Vigilance of the Interna-tional Society of Blood Transfusion (ISBT); Working Party on Hemovigilance in collaboration with The International Hae-movigilance Network and The American Association of Blood Banks (AABB) Donor Hemovigilance Working Group, De-cember 11, 2014. Available from: http://www.aabb.org/rese
arch/hemovigilance/Documents/Donor-Standard-Definitions
.pdf.
Goldman M, Land K, Robillard P, Wiersum-Osselton J. Develop-ment of standard definitions for surveillance of complications related to blood donation. Vox Sang 2016; 110(2): 185‒8.
Das SS, Sen S, Chakrabarty RI. Machine and man individuali-ties in apheresis adverse events. Global J Trans Med 2018; 3(1): 30‒3.
Bialkowski W, Bruhn R, Edgren G, Papanek P. Citrate antico-agulation: Are blood donors donating bone? J Clin Apher 2016; 31(5): 459–63.
Low on I transfusion medicine. ("Sl. glasnik RS", br. 40/17, 113/17).
Guan L, Tian X, Gombar S, Zemek AJ, Krishnan G, Scott R, et al. Big data modeling to predict platelet usage and minimize wastage in a tertiary care system. Proc Natl Acad Sci USA 2017; 114(43): 11368‒73.
Yu C, Lau JT, Zhong W, Huang X, Pan C, Chen Y, et al. Why some donors are more willing to donate platelets? – a qualita-tive study on 25 regular platelet donors in Guangzhou, China. BMC Public Health 2019; 19(1): 1671.
Estcourt JL, Birchall J, Allard S, Bassey JS, Hersey P, Kerr JP, et al. British Committee for Standards in Haematology. Guide-lines for the use of platelet transfusions. Br J Haematol 2017; 176(3): 365‒94.
Khajuria K, Sawhney V, Sharma R, Gupta S. Adverse donor re-action during and after plateletpheresis in a tertiary care cen-tre. Int J Res Med Sci 2017; 5(4): 1221‒3.
Diekamp U, Gneißl J, Rabe A, Kießig ST. Donor Hemovigilance with Blood Donation. Transfus Med Hemother 2015; 42(3): 181–92.
Navkudkar A, Desai P, Rajadhyaksha S. Effect of citrate on ionized calcium levels during plateletpheresis procedures. Vox Sang 2021; 16(1): 26–30.
Dogra K, Fulzele P, Rout D, Chaurasia R, Coshic P, Chatterjee K. Adverse Events During Apheresis Procedures: Audit at a Ter-tiary Hospital. Indian J Hematol Blood Transfus 2017; 33(1): 106‒8.
Shanthi B, Sudhir Kumar V, Mahesh K, Krishna BM. Adverse Events Associated with Plateletpheresis: A Tertiary Care Hos-pital Experience in Southern India. J Clin Diagn Res 2019; 13(5): EC10‒EC12.
Philip J, Sarkar RS, Pathak A. Adverse events associated with apheresis procedures: Incidence and relative frequency. Asian J Transfus Sci 2013; 7(1): 37–41.
Bassi R, Thakur KK, Bhardwaj K. Plateletpheresis adverse events in relation to donor and plateletpheresis session profile. Iraqi J Hematol 2017; 6: 38–42.